Figure 2.
Figure 2. Survival analysis of DLBCL patients stratified using FOXP1 expression. (A) Kaplan-Meier analysis of OS of 126 patients DLBCL stratified according to FOXP1 positivity. Patients with high FOXP1 expression had significantly inferior median OS compared with patients with negative and variable weak expression. (B) OS of 70 patients with DLCBL of a non-GC phenotype and BCL2 expression, stratified according to FOXP1 expression. High FOXP1 expression has an additive adverse prognostic effect and identifies a group of patients with very poor outcome, even within this already poor prognostic subgroup.

Survival analysis of DLBCL patients stratified using FOXP1 expression. (A) Kaplan-Meier analysis of OS of 126 patients DLBCL stratified according to FOXP1 positivity. Patients with high FOXP1 expression had significantly inferior median OS compared with patients with negative and variable weak expression. (B) OS of 70 patients with DLCBL of a non-GC phenotype and BCL2 expression, stratified according to FOXP1 expression. High FOXP1 expression has an additive adverse prognostic effect and identifies a group of patients with very poor outcome, even within this already poor prognostic subgroup.

Close Modal

or Create an Account

Close Modal
Close Modal